MX2015008171A - Formulacion que comprende agomelatina amorfa. - Google Patents

Formulacion que comprende agomelatina amorfa.

Info

Publication number
MX2015008171A
MX2015008171A MX2015008171A MX2015008171A MX2015008171A MX 2015008171 A MX2015008171 A MX 2015008171A MX 2015008171 A MX2015008171 A MX 2015008171A MX 2015008171 A MX2015008171 A MX 2015008171A MX 2015008171 A MX2015008171 A MX 2015008171A
Authority
MX
Mexico
Prior art keywords
formulation
agomelatine
composition
amorphous
amorphous agomelatine
Prior art date
Application number
MX2015008171A
Other languages
English (en)
Inventor
Lisardo Álvarez Fernández
Rolf Keltjens
Jacobus Theodorus Henricus Eupen Van
Deepak Murpani
Sonia Garcia Jimenez
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of MX2015008171A publication Critical patent/MX2015008171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición de agomelatina y un copolímero de ácido metacrílico y divinilbenceno, a una formulación farmacéutica que comprende la composición y al uso de ya sea la composición o la formulación como un medicamento particularmente para el tratamiento del trastorno depresivo mayor.
MX2015008171A 2012-12-20 2013-12-17 Formulacion que comprende agomelatina amorfa. MX2015008171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2012076366 2012-12-20
PCT/EP2013/076842 WO2014095818A1 (en) 2012-12-20 2013-12-17 Formulation comprising amorphous agomelatine

Publications (1)

Publication Number Publication Date
MX2015008171A true MX2015008171A (es) 2015-09-16

Family

ID=49766107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008171A MX2015008171A (es) 2012-12-20 2013-12-17 Formulacion que comprende agomelatina amorfa.

Country Status (2)

Country Link
MX (1) MX2015008171A (es)
WO (1) WO2014095818A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2705023A4 (en) * 2011-01-04 2014-11-19 Symed Labs Ltd PROCESSES FOR THE PREPARATION OF N- [2- (7-METHOXY-1-NAPHTHYLLELYHYL) ACETAMIDE
WO2017059877A1 (en) * 2015-10-07 2017-04-13 Rontis Hellas S.A. Pharmaceutical composition containing agomelatine and process for the preparation thereof
EP3466413A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2018160T3 (da) * 2006-03-16 2012-02-06 Tris Pharma Inc Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
CN101836966A (zh) * 2010-05-27 2010-09-22 北京万全阳光医药科技有限公司 一种含有阿戈美拉汀的口腔崩解片

Also Published As

Publication number Publication date
WO2014095818A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
NZ702663A (en) Nuclear transport modulators and uses thereof
TN2015000278A1 (en) Autotaxin inhibitors
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12014501702A1 (en) Imidazopyrrolidinone compounds
PH12014501984A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
MX2015006234A (es) Uso de akkermansia para tratar trastornos metabolicos.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
HK1197235A1 (zh) 二氫吡唑、其藥物組合物及其治療生育障礙的用途
PL2903608T3 (pl) Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych
MX2015008171A (es) Formulacion que comprende agomelatina amorfa.
EP2886112A4 (en) COMPOSITION CONTAINING AS ACTIVE INGREDIENT OF S-ALLYL-L-CYSTEINE FOR PREVENTING OR TREATING OCULAR DISEASES, AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME
HK1219063A1 (zh) 包含透明質酸的藥物組合物用於治療黑椎間盤疾病
WO2014013090A3 (en) Formulation comprising amorphous fingolimod
GB201115977D0 (en) Neurodevelopmental disorders
IN2014DN10683A (es)
WO2013109202A3 (en) Pharmaceutical compounds comprising cefetamet
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز
IN2013MU01239A (es)
IN2013MU01242A (es)
IN2013MU01241A (es)
IN2013MU01240A (es)